RELAPSED / REFRACTORY AML
Clinical trials for RELAPSED / REFRACTORY AML explained in plain language.
Never miss a new study
Get alerted when new RELAPSED / REFRACTORY AML trials appear
Sign up with your email to follow new studies for RELAPSED / REFRACTORY AML, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New targeted drug shows promise for tough blood cancers in early trial
Disease control OngoingThis early study tests a new drug called BYON4413 in 16 people whose acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS) have not responded to standard treatments. The main goals are to check the drug's safety and find the right dose, while also looking for signs that…
Matched conditions: RELAPSED / REFRACTORY AML
Phase: PHASE1 • Sponsor: Byondis B.V. • Aim: Disease control
Last updated May 17, 2026 11:37 UTC
-
New pill shows promise for tough blood cancers in early trial
Disease control OngoingThis early-phase study tests an experimental oral drug called AUTX-703 in about 34 adults whose acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) have returned or not responded to standard treatments. The main goals are to check the drug's safety, find the best dose…
Matched conditions: RELAPSED / REFRACTORY AML
Phase: PHASE1 • Sponsor: Auron Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 11:32 UTC
-
New antibody combo targets tough blood cancers
Disease control OngoingThis study tests a new drug called bexmarilimab, given with standard treatments, for people with certain blood cancers (MDS, CMML, or AML). The first part finds a safe dose, and the second part checks if the combination helps control the cancer. About 181 adults will take part.
Matched conditions: RELAPSED / REFRACTORY AML
Phase: PHASE1, PHASE2 • Sponsor: Faron Pharmaceuticals Ltd • Aim: Disease control
Last updated May 14, 2026 12:06 UTC